CAMBRIDGE, Mass.--(BUSINESS WIRE)--Harvard University’s Office of Technology Development today announced that it has signed a multi-year license and sponsored research agreement with Merck & Co., Inc. to advance an innovative line of research focused on developing new therapies for the treatment of osteoporosis.
